TrueBeam™ System For Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval
6/16/2011
Varian Medical Systems, Inc. (NYSE: VAR), the world's leading manufacturer of medical technology for treating cancer with radiotherapy, announced it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the TrueBeam™ system for image-guided radiotherapy and radiosurgery in Japan...
igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC)...
Immune Response To Tumour Cells Could Aid Cancer Battle
6/16/2011
A new research at the University of Leicester has developed a novel immunotherapeutic approach with potential for cancer treatment. Malignant tumours are the second main cause of death worldwide, with haematological malignancies representing 10%...
Cell Phone Range Outside Most Brain Tumor Locations
6/16/2011
Cell phone radiation cannot reach the cells where most brain tumors are located - so, is their alleged link to brain cancer in some studies misplaced? Study author, Dr...
The U.S. Food and Drug Administration approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue...
Skin Cancer Risk Baseball Caps, Flip-Flops And Driving With The Window Open
6/15/2011
Baseball caps expose your ears to dangerous sun damage, while flip-flops do not cover the tops of feet - increasing the risk of skin cancer in both areas of the body, researchers from Loyola University Medical Center in Maywood, Ill, explained...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that nearly half of surveyed urologists view the approval of Dendreon's Provenge as a breakthrough in the treatment of prostate cancer, compared with 31 percent of surveyed oncologists. However, oncologists prescribe the agent more frequently than urologists...
Orexo: Abstral(R) Launches In Canada
6/15/2011
Through its local partner, Orexo (STO:ORX) now initiates marketing and sales of the pain treatment Abstral in Canada. In 2008, ProStrakan, who markets Abstral in Europe and the U.S., licensed its rights in the Canadian market to Paladin Labs Inc., which now launches the treatment of breakthrough pain in cancer patients in the Canadian market...
Ovarian Cancer Cells Force Their Way Through Tissue
6/15/2011
A team led by Joan Brugge, the Louise Foote Pfeiffer Professor of Cell Biology at Harvard Medical School, recently shed light on how ovarian cancer spreads...
Nuvilex Enters Discussions To Acquire Next Generation Technology To Treat Multiple Types Of Cancer
6/15/2011
Nuvilex, Inc. (OTCQB: NVLX) announced today it has entered into discussions to acquire the next generation live cell encapsulation technology that serves as the platform for multiple cancer therapies...